Condition
Urinary Tract Infection (UTI)
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results75% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (3)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Recruiting1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02829060Not ApplicableCompleted
Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
NCT04095572Phase 4Recruiting
Alternative Prophylaxis in Female Recurrent Urinary Tract Infections
NCT03697096Not ApplicableCompletedPrimary
The INSPIRE-ASP UTI Trial
NCT02728089Phase 3CompletedPrimary
Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
NCT01818180Not ApplicableTerminatedPrimary
Urell and Pregnancy
Showing all 5 trials